The Brain Tumour Charity Translational Award 2026 provides up to £400,000 over 18 months to advance promising innovations for people with primary brain tumours. The opportunity is open internationally to academic researchers and eligible commercial organisations.
The award supports projects that have progressed beyond discovery and need focused validation before moving towards clinical evaluation. Eligible approaches include therapeutics, diagnostics, drug-delivery systems, medical devices, surgical or imaging technologies, and software-based clinical tools. Projects should generate evidence that informs the next development step and helps attract further funding or partnerships.
Eligibility Criteria
- Researchers and eligible organisations worldwide may apply.
- Academic teams and commercial organisations are eligible; commercial applicants must justify the need for charitable funding.
- Projects must address primary brain tumours and align with the Charity’s research priorities.
- Applicants must present a defined innovation with a clear intended clinical use.
- Credible preliminary evidence must support the proposed validation work.
- Teams must have the expertise needed to deliver the project and advance its translation.
- Each researcher may lead only one proposal per grant round.
Funding Details
- Maximum funding: £400,000.
- Duration: Up to 18 months.
- Supported work: Focused preclinical validation or product development.
Deadline
- Outline application: November 25, 2026, at 1:00 p.m. GMT.
- Full application invitations: March 17, 2027.
- Invited full application: May 12, 2027, at 1:00 p.m. BST.
Further Information
- Official program details and application portal
- Contact: research@thebraintumourcharity.org
- Outline applications require a two-page supporting-data document demonstrating the innovation’s readiness.